Multiple Myeloma Newsflash: Emerging Data From the 2020 ASH Annual Meeting

Multiple Myeloma Newsflash: Emerging Data From the 2020 ASH Annual Meeting

Multiple Myeloma Newsflash: Emerging Data From the 2020 ASH Annual Meeting

In this recap form of the 2020 ASH Annual Meeting, discover potentially practice-changing data and stay up to date on the latest in multiple myeloma.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    A 15-minute synopsis of the top hematology research in multiple myeloma presented at the 2020 ASH Annual Meeting. Learn about potential practice-changing data placed in a real-world context by a myeloma expert. This activity is an opportunity to stay up to date on the rapidly evolving myeloma landscape and to enhance your management and care strategies for patients with multiple myeloma.

  • Activity Planners

    Brad Bongiovanni, ND
    Director, Medical Affairs
    Baltimore, MD 

    Amy Burdette, PhD
    Manager, Educational Strategy & Content
    Baltimore, MD 

    Samantha Gordon, MS
    Accreditation Manager
    Baltimore, MD 

    Amy Sison
    Director of CME
    Baltimore, MD

  • Faculty

    Joseph Mikhael, MD, MEd, FRCPC, FACP   
    Professor, Applied Cancer Research and Drug Discovery  
    Translational Genomics Research Institute
    City of Hope Cancer Center  
    Chief Medical Officer, International Myeloma Foundation  
    Phoenix, AZ 

  • Disclosure of Conflicts of Interest

    Disclosure Policy
    Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

    Disclosure Statement
    The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 

    Joseph Mikhael, MD, MEd, FRCPC, FACP  
    Fees received for promotional/non-CME activities: Amgen, Bristol Meyers-Squibb, GlaxoSmithKline, Janssen Pharmaceuticals North America, Sanofi U.S. Inc., Takeda Pharmaceuticals, U.S.A., Inc.

    The peer reviewers and activity planners have no financial relationships to disclose.

    Off-label/unapproved drug uses or products are mentioned within this activity.

  • Statement of Need

    Annual meetings held by professional societies are a leading venue for the presentation of practice-changing data in hematology/oncology. Each winter, the premier hematology conference, the ASH Annual Meeting, occurs with the presentation of more than 3,000 meeting abstracts. Hematologist/oncologists rely heavily on this conference to disseminate new scientific information given the diversity of practice-changing data presented each year. Hematologist/oncologists need resources to stay apprised of ongoing, potentially practice-changing clinical trials that may be appropriate treatment options for their patients with multiple myeloma.

  • Target Audience

    This activity is intended for hematologist/oncologists.

  • Learning Objective

    Upon completion, participants should be able to:

    • Discuss the potential clinical implications of emerging data in multiple myeloma
  • Accreditation and Credit Designation Statements

    Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

  • Commercial Support

    This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi Genzyme.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free